B cells in nasopharyngeal carcinoma: From prognostic signal to therapeutic hypothesis-A critical appraisal of the RATIONALE-309 biomarker analysis.
Adding immunotherapy to chemotherapy sustained survival benefits in advanced nasopharyngeal cancer over three years.
This PubMed record reports the 3-year follow-up of the phase 3 RATIONALE-309 trial confirmed sustained progression-free and overall survival (OS) benefit with tislelizumab plus gemcitabine-cisplatin in recurrent/metastatic nasopharyngeal carcinoma (R/M NPC). The study was classified as randomized controlled trial and is relevant to treatment innovation.
What the study was
- Study design
- Randomized controlled trial
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Translational oncology
Why it surfaced
Conservative triage based on the PubMed abstract, randomized controlled trial, clinical relevance, and unmet-need signals.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.